Trial · NCT00923013
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 34 | |
| Overall Study | STARTED | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 32 | |
| Overall Study | STARTED | Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 34 | |
| Overall Study | STARTED | Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 30 | |
| Overall Study | STARTED | Cohort 2 Arm 3 SubGroup 1-Cladribine (Rituximab Before 1st of 5 Daily Doses of Cladribine on Day 1) | 25 | |
| Overall Study | STARTED | Cohort 3Arm3 HairyCell LeukemiaVariant-Cladribine +(Rituximab Before 1st of 5 Daily Doses Cladribine | 20 | |
| Overall Study | Disease Progression on Study | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 1 | |
| Overall Study | Disease Progression on Study | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 0 | |
| Overall Study | Disease Progression on Study | Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 0 | |
| Overall Study | Disease Progression on Study | Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 0 | |
| Overall Study | Disease Progression on Study | Cohort 2 Arm 3 SubGroup 1-Cladribine (Rituximab Before 1st of 5 Daily Doses of Cladribine on Day 1) | 0 | |
| Overall Study | Disease Progression on Study | Cohort 3Arm3 HairyCell LeukemiaVariant-Cladribine +(Rituximab Before 1st of 5 Daily Doses Cladribine | 4 | |
| Overall Study | Refused Further Follow-up | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 1 | |
| Overall Study | Refused Further Follow-up | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 0 | |
| Overall Study | Refused Further Follow-up | Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 0 | |
| Overall Study | Refused Further Follow-up | Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 0 | |
| Overall Study | Refused Further Follow-up | Cohort 2 Arm 3 SubGroup 1-Cladribine (Rituximab Before 1st of 5 Daily Doses of Cladribine on Day 1) | 0 | |
| Overall Study | Refused Further Follow-up | Cohort 3Arm3 HairyCell LeukemiaVariant-Cladribine +(Rituximab Before 1st of 5 Daily Doses Cladribine | 0 | |
| Overall Study | Death During Follow-up Period | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 0 | |
| Overall Study | Death During Follow-up Period | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00923013/flow